| Filed | Description | |
|---|---|---|
| 2/13/25 | 1.011.02 Material Agreement · Agreement Terminated | → |
| 2/11/25 | 1.01 Material Agreement | → |
| 10/25/24 | 1.01 Material Agreement | → |
| 7/3/24 | 1.011.02 Material Agreement · Agreement Terminated | → |
| 6/24/24 | 1.01 Material Agreement | → |
| 6/6/24 | 1.011.02 Material Agreement · Agreement Terminated | → |
| ↓ 12 more | ||
S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency (X-SCID).